BRAF and metastatic melanoma: More recently, the clinical and histologic features of cSCCs and other squamoproliferative lesions that complicate treatment for metastatic melanoma with oral small molecule BRAF inhibitors (BRAFi) have raised the possibility of significant viral involvement in their pathogenesis (Boussemart et al., 2013).